These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10091437)

  • 1. Modernizing the FDA: an incremental revolution.
    Merrill RA
    Health Aff (Millwood); 1999; 18(2):96-111. PubMed ID: 10091437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New FDA Center May Speed Approval Process.
    Cancer Discov; 2016 Sep; 6(9):OF5. PubMed ID: 27417310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA plan for statutory compliance. Notice of availability.
    Fed Regist; 1998 Nov; 63(226):65000-40. PubMed ID: 10338873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Device standards: the view from the FDA.
    Cangelosi RJ
    J Clin Eng; 1980; 5(1):9-12. PubMed ID: 10246341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delegations of authority and organization; Center for Devices and Radiological Health--FDA. Final rule.
    Fed Regist; 1991 Oct; 56(197):51169-70. PubMed ID: 10115059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Regulation of Neurological and Physical Medicine Devices: Access to Safe and Effective Neurotechnologies for All Americans.
    Anderson L; Antkowiak P; Asefa A; Ballard A; Bansal T; Bello A; Berne B; Bowsher K; Blumenkopf B; Broverman I; Bydon M; Chao K; Como P; Cork K; Costello A; De Laurentis K; DeMarco A; Dean H; Doucet J; Dworak B; Epperson L; Franca E; Ghassemian N; Ghosh C; Govindarajan A; Gupta J; Gutowski S; Herrmann R; Hoffmann M; Heetderks W; Hsu S; Kaufman D; Keegan E; Kittlesen G; Khuu K; Lee H; Lo L; Marcus I; Marjenin T; Mathews B; Misra S; Pinto V; Ramos V; Raben S; Russell A; Saha D; Seog J; Shenouda C; Smith M; Tang X; Wachrathit K; Waterhouse J; Williams D; Zheng X; Peña C
    Neuron; 2016 Dec; 92(5):943-948. PubMed ID: 27930909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of the US Food and Drug Administration's reform legislation.
    Rheinstein PH
    Clin Ther; 1998; 20 Suppl C():C4-11. PubMed ID: 9915084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should preemption apply in a pharmaceutical context? An analysis of the preemption debate and what regulatory compliance statutes contribute to the discussion.
    Surprenant JA
    Fordham Law Rev; 2008 Oct; 77(1):327-63. PubMed ID: 18982554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Evidence, Public Participation, and the FDA.
    Schwartz JL
    Hastings Cent Rep; 2017 Nov; 47(6):7-8. PubMed ID: 29171057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA recognition of consensus standards in the premarket notification program.
    Marlowe DE; Phillips PJ
    Biomed Instrum Technol; 1998; 32(3):301-4. PubMed ID: 9619259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA'S food ingredient approval process: Safety assurance based on scientific assessment.
    Rulis AM; Levitt JA
    Regul Toxicol Pharmacol; 2009 Feb; 53(1):20-31. PubMed ID: 18983884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical device review at the Food and Drug Administration: lessons from magnetic resonance spectroscopy and biliary lithotripsy.
    Makow LS
    Stanford Law Rev; 1994 Feb; 46(3):709-46. PubMed ID: 10171820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA reform in Congress: FDA's concerns. Food and Drug Administration.
    James JS
    AIDS Treat News; 1996 Apr; (no 245):5-7. PubMed ID: 11363624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assignment of agency component for review of premarket applications--FDA. Final rule.
    Fed Regist; 1991 Nov; 56(225):58754-8. PubMed ID: 10115697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Modernization Act: implications for oncology.
    Morris L
    Oncology (Williston Park); 1998 Nov; 12(11A):139-41. PubMed ID: 10028506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Off-label use of medical products in radiation therapy: summary of the report of AAPM Task Group No. 121.
    Thomadsen BR; Heaton HT; Jani SK; Masten JP; Napolitano ME; Ouhib Z; Reft CS; Rivard MJ; Robin TT; Subramanian M; Suleiman OH
    Med Phys; 2010 May; 37(5):2300-11. PubMed ID: 20527564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advisory committees; establishment and termination--FDA. Final rule.
    Fed Regist; 1990 Dec; 55(240):51281-2. PubMed ID: 10108582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coming closer to FDA reform.
    Cimmons M
    Nat Med; 1997 Sep; 3(9):940. PubMed ID: 9288707
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.